InspireMD Advances Embolic Protection Stent Technology

InspireMD Inc. is making progress with its proprietary emboli-trapping InspireMD Embolic Protection Stent (EPS) platform technology for use primarily in patients with embolic-risk acute coronary syndromes, such as myocardial infarction and saphenous vein graft coronary interventions.

Boston, MA- and Tel-Aviv-based InspireMD Inc. is making progress with its proprietary emboli-trapping InspireMD Embolic Protection Stent (EPS) platform technology for use primarily in patients with embolic-risk acute coronary syndromes, such as myocardial infarction (AMI) and saphenous vein graft coronary interventions. The device has an expandable MicroNet, an ultrathin, circular-knitted polyethylene terephthalate (PET) micron mesh sleeve attached to the proximal and distal edges of the stent, covering 20% of its surface. The MicroNet is designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization – a major issue with ST segment elevation myocardial infarction (STEMI) patients – without affecting stent deliverability or deployment. The original histology work for the mesh technology was done at the Massachusetts Institute of Technology under the direction of Elazer Edelman, MD, PhD, a prominent cardiologist at Brigham and Women's Hospital in Boston.

"Ours is the first simple, integrated stent system focused on myocardial salvage and mortality improvement that has delivered early, very...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.